Evoke Pharma is a biotechnology company focused on developing and commercializing innovative treatments for gastrointestinal disorders, particularly those affecting the gastrointestinal tract and leading to issues such as gastroparesis. Their primary objective is to create therapeutic solutions that enhance patient care and address unmet medical needs within this specialized area. By leveraging their expertise in drug development and a deep understanding of gastrointestinal diseases, Evoke Pharma aims to improve the quality of life for patients suffering from these challenging conditions. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fair to Evoke shareholders.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036.
Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office Notice of Allowance for a new patent on its lead product, GIMOTI.
